234 related articles for article (PubMed ID: 9484373)
1. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.
Schoenen J; Jacquy J; Lenaerts M
Neurology; 1998 Feb; 50(2):466-70. PubMed ID: 9484373
[TBL] [Abstract][Full Text] [Related]
2. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial.
MacLennan SC; Wade FM; Forrest KM; Ratanayake PD; Fagan E; Antony J
J Child Neurol; 2008 Nov; 23(11):1300-4. PubMed ID: 18984840
[TBL] [Abstract][Full Text] [Related]
3. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.
Maizels M; Blumenfeld A; Burchette R
Headache; 2004 Oct; 44(9):885-90. PubMed ID: 15447697
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.
Magis D; Ambrosini A; Sándor P; Jacquy J; Laloux P; Schoenen J
Headache; 2007 Jan; 47(1):52-7. PubMed ID: 17355494
[TBL] [Abstract][Full Text] [Related]
5. Riboflavin prophylaxis in pediatric and adolescent migraine.
Condò M; Posar A; Arbizzani A; Parmeggiani A
J Headache Pain; 2009 Oct; 10(5):361-5. PubMed ID: 19649688
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of low-dose riboflavin as a prophylactic agent in pediatric migraine.
Yamanaka G; Suzuki S; Takeshita M; Go S; Morishita N; Takamatsu T; Daida A; Morichi S; Ishida Y; Oana S; Nara S; Shimura M; Nishimata S; Kawashima H
Brain Dev; 2020 Aug; 42(7):523-528. PubMed ID: 32336482
[TBL] [Abstract][Full Text] [Related]
7. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study.
Schoenen J; Lenaerts M; Bastings E
Cephalalgia; 1994 Oct; 14(5):328-9. PubMed ID: 7828189
[TBL] [Abstract][Full Text] [Related]
8. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial.
Bruijn J; Duivenvoorden H; Passchier J; Locher H; Dijkstra N; Arts WF
Cephalalgia; 2010 Dec; 30(12):1426-34. PubMed ID: 20974610
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
[TBL] [Abstract][Full Text] [Related]
11. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.
Sándor PS; Di Clemente L; Coppola G; Saenger U; Fumal A; Magis D; Seidel L; Agosti RM; Schoenen J
Neurology; 2005 Feb; 64(4):713-5. PubMed ID: 15728298
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of high-dose riboflavin in migraine prophylaxis.
Yee AJ
Neurology; 1999 Jan; 52(2):431-2. PubMed ID: 9932987
[No Abstract] [Full Text] [Related]
16. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Tronvik E; Stovner LJ; Helde G; Sand T; Bovim G
JAMA; 2003 Jan; 289(1):65-9. PubMed ID: 12503978
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials.
Sándor PS; Afra J; Ambrosini A; Schoenen J
Headache; 2000 Jan; 40(1):30-5. PubMed ID: 10759900
[TBL] [Abstract][Full Text] [Related]
20. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
Diener HC; Agosti R; Allais G; Bergmans P; Bussone G; Davies B; Ertas M; Lanteri-Minet M; Reuter U; Sánchez Del Río M; Schoenen J; Schwalen S; van Oene J;
Lancet Neurol; 2007 Dec; 6(12):1054-62. PubMed ID: 17988947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
